Replication-competent herpes simplex vectors: design and applications

被引：10

作者：

Argnani, R ^{[1
]}

Lufino, M ^{[1
]}

Manservigi, M ^{[1
]}

Manservigi, R ^{[1
]}

机构：

[1] Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, I-44100 Ferrara, Italy

来源：

GENE THERAPY | 2005年 / 12卷 / Suppl 1期

关键词：

viral vectors; HSV; targeting; tumors;

D O I：

10.1038/sj.gt.3302622

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Replication-competent vectors are derived from attenuated viruses whose genes, that are nonessential for replication in cultured cells in vitro, are either mutated or deleted. The removal of one or more nonessential genes may reduce pathogenicity without requiring a cell line to complement growth. Herpes simplex viruses (HSV) are potential vectors for several applications in human healthcare. These include delivery and expression of human genes to cells of the nervous systems, selective destruction of cancer cells, prophylaxis against infection with HSV or other infectious diseases, and targeted infection to specific tissues or organs. This review highlights the progress in creating attenuated genetically engineered HSV vectors.

引用

页码：S170 / S177

页数：8

共 78 条

[1]

Aghi M, 1999, CANCER RES, V59, P3861

[2]

Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies [J].

Aghi, M ;

Kramm, CM ;

Chou, TC ;

Breakefield, XO ;

Chiocca, EA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (05) :370-380

[3]

Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry [J].

Anderson, DB ;

Laquerre, S ;

Goins, WF ;

Cohen, JB ;

Glorioso, JC .

JOURNAL OF VIROLOGY, 2000, 74 (05) :2481-2487

[4]

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins [J].

Andreansky, S ;

He, B ;

van Cott, J ;

McGhee, J ;

Markert, JM ;

Gillespie, GY ;

Roizman, B ;

Whitley, RJ .

GENE THERAPY, 1998, 5 (01) :121-130

[5]

Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide [J].

Argnani, R ;

Boccafogli, L ;

Marconi, PC ;

Manservigi, R .

GENE THERAPY, 2004, 11 (13) :1087-1098

[6]

Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10) [J].

Aurelian, L ;

Kokuba, H ;

Smith, CC .

VACCINE, 1999, 17 (15-16) :1951-1963

[7]

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer [J].

Bennett, JJ ;

Malhotra, S ;

Wong, RJ ;

Delman, K ;

Zager, J ;

St-Louis, M ;

Johnson, P ;

Fong, Y .

ANNALS OF SURGERY, 2001, 233 (06) :819-826

[8]

Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations [J].

Bernstein, DI ;

Ireland, J ;

Bourne, N .

ANTIVIRAL RESEARCH, 2000, 47 (03) :159-169

[9]

BOVIATSIS EJ, 1994, CANCER RES, V54, P5745

[10]

BOVIATSIS EJ, 1994, GENE THER, V1, P323

← 1 2 3 4 5 6 7 8 →